In the present study we showed that Gal-1 overexpression leads to comparative HCC cell resistance to sorafenib in vitro, furthermore, despite a small cohort, clinical data also indicate that high levels of Gal-1 lead to HCC sorafenib resistance. Here, LGALS1 is linked to hepatocellular carcinoma.